Literature DB >> 11880402

Human immunodeficiency virus type 1 group m protease in cameroon: genetic diversity and protease inhibitor mutational features.

Peter N Fonjungo1, Eitel N Mpoudi, Judith N Torimiro, George A Alemnji, Laura T Eno, Esther J Lyonga, John N Nkengasong, Renu B Lal, Mark Rayfield, Marcia L Kalish, Thomas M Folks, Danuta Pieniazek.   

Abstract

To establish a baseline for monitoring resistance to protease inhibitors (PIs) and examining the efficacy of their use among persons in Cameroon infected with human immunodeficiency virus type 1 (HIV-1), we analyzed genetic variability and PI resistance-associated substitutions in PCR-amplified protease (PR) sequences in strains isolated from 110 HIV-1-infected, drug-naïve Cameroonians. Of the 110 strains, 85 were classified into six HIV-1 PR subtypes, A (n = 1), B (n = 1), F (n = 4), G (n = 7), H (n = 1), and J (n = 7), and a circulating recombinant form, CRF02-AG (n = 64). PR genes from the remaining 25 (23%) specimens were unclassifiable, whereas 2% (7 of 301) unclassifiable PR sequences were reported for a global collection. Two major PI resistance-associated mutations, 20M and 24I, were detected in strains from only two specimens, whereas secondary mutations were found in strains from all samples except one strain of subtype B and two strains of CRF02-AG. The secondary mutations showed the typical PI resistance-associated pattern for non-subtype B viruses in both classifiable and unclassifiable PR genes, with 36I being the predominant (99%) mutation, followed by 63P (18%), 20R (15%), 77I (13%), and 10I or 10V (11%). Of these mutations, dual and triple PI resistance-associated substitutions were found in 38% of all the Cameroonian strains. Compared with classifiable PR sequences, unclassifiable sequences had significantly more dual and triple substitutions (64% versus 30%; P = 0.004). Phenotypic and clinical evaluations are needed to estimate whether PI resistance during antiretroviral drug treatment occurs more rapidly in individuals infected with HIV-1 strains harboring multiple PI resistance-associated substitutions. This information may be important for determination of appropriate drug therapies for HIV-1-infected persons in Cameroon, where more than one-third of HIV-1 strains were found to carry dual and triple minor PI resistance-associated mutations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11880402      PMCID: PMC120267          DOI: 10.1128/JCM.40.3.837-845.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  38 in total

1.  HIV-1 nomenclature proposal.

Authors:  D L Robertson; J P Anderson; J A Bradac; J K Carr; B Foley; R K Funkhouser; F Gao; B H Hahn; M L Kalish; C Kuiken; G H Learn; T Leitner; F McCutchan; S Osmanov; M Peeters; D Pieniazek; M Salminen; P M Sharp; S Wolinsky; B Korber
Journal:  Science       Date:  2000-04-07       Impact factor: 47.728

2.  Most env and gag subtype A HIV-1 viruses circulating in West and West Central Africa are similar to the prototype AG recombinant virus IBNG.

Authors:  C Montavon; C Toure-Kane; F Liegeois; E Mpoudi; A Bourgeois; L Vergne; J L Perret; A Boumah; E Saman; S Mboup; E Delaporte; M Peeters
Journal:  J Acquir Immune Defic Syndr       Date:  2000-04-15       Impact factor: 3.731

3.  Phylogenetic analysis of protease and transmembrane region of HIV type 1 group O.

Authors:  C Yang; F Gao; P N Fonjungo; L Zekeng; G van der Groen; D Pieniazek; C Schable; R B Lal
Journal:  AIDS Res Hum Retroviruses       Date:  2000-07-20       Impact factor: 2.205

4.  Evidence of a high frequency of HIV-1 subtype F infections in a heterosexual population in Buenos Aires, Argentina.

Authors:  S Masciotra; B Livellara; W Belloso; L Clara; A Tanuri; A C Ramos; J Baggs; R Lal; D Pieniazek
Journal:  AIDS Res Hum Retroviruses       Date:  2000-07-01       Impact factor: 2.205

Review 5.  Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies.

Authors:  J W Erickson; S V Gulnik; M Markowitz
Journal:  AIDS       Date:  1999       Impact factor: 4.177

6.  Presence of diverse human immunodeficiency virus type 1 viral variants in Cameroon.

Authors:  P N Fonjungo; E N Mpoudi; J N Torimiro; G A Alemnji; L T Eno; J N Nkengasong; F Gao; M Rayfield; T M Folks; D Pieniazek; R B Lal
Journal:  AIDS Res Hum Retroviruses       Date:  2000-09-01       Impact factor: 2.205

7.  Presence of human immunodeficiency virus (HIV) type 1, group M, non-B subtypes, Bronx, New York: a sentinel site for monitoring HIV genetic diversity in the United States.

Authors:  P J Weidle; C E Ganea; K L Irwin; D Pieniazek; J P McGowan; N Olivo; A Ramos; C Schable; R B Lal; S D Holmberg; J A Ernst
Journal:  J Infect Dis       Date:  2000-02       Impact factor: 5.226

8.  Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group.

Authors:  D Pieniazek; M Rayfield; D J Hu; J Nkengasong; S Z Wiktor; R Downing; B Biryahwaho; T Mastro; A Tanuri; V Soriano; R Lal; T Dondero
Journal:  AIDS       Date:  2000-07-28       Impact factor: 4.177

9.  Distribution of HIV-1 subtypes among HIV-seropositive patients in the interior of Côte d'Ivoire.

Authors:  J N Nkengasong; C C Luo; L Abouya; D Pieniazek; C Maurice; M Sassan-Morokro; D Ellenberger; D J Hu; C P Pau; T Dobbs; R Respess; D Coulibaly; I M Coulibaly; S Z Wiktor; A E Greenberg; M Rayfield
Journal:  J Acquir Immune Defic Syndr       Date:  2000-04-15       Impact factor: 3.731

10.  Genetic analysis of human immunodeficiency virus in Abidjan, Ivory Coast reveals predominance of HIV type 1 subtype A and introduction of subtype G.

Authors:  D L Ellenberger; D Pieniazek; J Nkengasong; C C Luo; S Devare; C Maurice; M Janini; A Ramos; C Fridlund; D J Hu; I M Coulibaly; E Ekpini; S Z Wiktor; A E Greenberg; G Schochetman; M A Rayfield
Journal:  AIDS Res Hum Retroviruses       Date:  1999-01-01       Impact factor: 2.205

View more
  14 in total

1.  Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy.

Authors:  Patrícia A Brindeiro; Rodrigo M Brindeiro; Cláudio Mortensen; Kurt Hertogs; Veronique De Vroey; Norma P M Rubini; Fernando S Sion; Carlos A M De Sá; Deisy M Machado; Regina C M Succi; Amilcar Tanuri
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

2.  Transmitted drug resistance in nonsubtype B HIV-1 infection.

Authors:  Philip A Chan; Rami Kantor
Journal:  HIV Ther       Date:  2009-09-01

3.  Mutation T74S in HIV-1 subtype B and C proteases resensitizes them to ritonavir and indinavir and confers fitness advantage.

Authors:  Esmeralda A Soares; André F Santos; Luis M Gonzalez; Matthew S Lalonde; Denis M Tebit; Amilcar Tanuri; Eric J Arts; Marcelo A Soares
Journal:  J Antimicrob Chemother       Date:  2009-08-26       Impact factor: 5.790

4.  Diversity of human immunodeficiency virus type 1 subtype A and CRF03_AB protease in Eastern Europe: selection of the V77I variant and its rapid spread in injecting drug user populations.

Authors:  Nikita I Roudinskii; Anna L Sukhanova; Elena V Kazennova; Jonathan N Weber; Vadim V Pokrovsky; Vladimir M Mikhailovich; Aleksei F Bobkov
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

5.  Molecular characterization of human immunodeficiency virus type 1 (HIV-1) and HIV-2 in Yaounde, Cameroon: evidence of major drug resistance mutations in newly diagnosed patients infected with subtypes other than subtype B.

Authors:  Nicaise Ndembi; Awet Abraha; Heather Pilch; Hiroshi Ichimura; Dora Mbanya; Lazare Kaptue; Robert Salata; Eric J Arts
Journal:  J Clin Microbiol       Date:  2007-09-12       Impact factor: 5.948

6.  Recombination confounds the early evolutionary history of human immunodeficiency virus type 1: subtype G is a circulating recombinant form.

Authors:  Ana B Abecasis; Philippe Lemey; Nicole Vidal; Túlio de Oliveira; Martine Peeters; Ricardo Camacho; Beth Shapiro; Andrew Rambaut; Anne-Mieke Vandamme
Journal:  J Virol       Date:  2007-06-06       Impact factor: 5.103

Review 7.  Evolution and diversity of HIV-1 in Africa--a review.

Authors:  Maria A Papathanasopoulos; Gillian M Hunt; Caroline T Tiemessen
Journal:  Virus Genes       Date:  2003       Impact factor: 2.332

8.  HIV Genetic Diversity and Drug Resistance.

Authors:  André F Santos; Marcelo A Soares
Journal:  Viruses       Date:  2010-02-02       Impact factor: 5.818

9.  Current status of HIV/AIDS in Cameroon: how effective are control strategies?

Authors:  Dora Mbanya; Martyn Sama; Paul Tchounwou
Journal:  Int J Environ Res Public Health       Date:  2008-12       Impact factor: 3.390

10.  HIV-1 CRF 02 AG polymerase genes in Southern Ghana are mosaics of different 02 AG strains and the protease gene cannot infer subtypes.

Authors:  Kwamena W Sagoe; Magda Dwidar; Theophilus K Adiku; Max Q Arens
Journal:  Virol J       Date:  2009-02-26       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.